UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

(Mark  One)

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT  OF  1934

     For  the  quarterly  period  ended  March  31,  2007

                                       OR

[]   TRANSITION  REPORT  PURUSANT  TO  SECTION  13  OR  15(d)  OF  THE
     SECURITIES  EXCHANGE  ACT  OF  1934

                        Commission file number 33-19598-D

                                    VYTA CORP
                                    ---------
        (Exact name of small business issuer as specified in its charter)

               Nevada                                   84-0992908
               ------                                   ----------
     (State or other jurisdiction of                 (I.R.S. employer
      incorporation or organization)              identification  number)

                           370 17th Street, Suite 3640
                             Denver, Colorado 80202
                    (Address of principal executive offices)

         Issuer's telephone number, including area code:  (303) 592-1010

Check  whether  the  issuer  (1)  has  filed all reports required to be filed by
Section 13(a) or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports),  and  (2) has been subject to such filing requirements for the past 90
days.      Yes  X      No
               ---        ---

Indicate  by check mark whether the registrant is a shell company (as defined in
Rule  12b-2  of  the  Exchange  Act).     Yes            No  X
                                              ---           ---

State the number of shares outstanding of each of the issuer's classes of common
equity,  as  of  the  latest  practicable  date:

As of May 19, 2007 there were 26,053,512 shares of the registrant's sole class
of common shares outstanding.

Transitional  Small  Business  Disclosure  Format          Yes         No  X
                                                               ---        ---


<PAGE>
<TABLE>
<CAPTION>
PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements(Unaudited)                                        Page
                                                                                ----
<S>                                                                             <C>
     Condensed Consolidated Balance Sheet -March 31, 2007                        F-1

     Condensed Consolidated Statements of Operations - Three and Nine
          months ended March 31, 2007 and 2006                                   F-2

     Condensed Consolidated Statements of Comprehensive Loss - Three and
          Nine months ended March 31, 2007 and 2006                              F-3

     Condensed Consolidated Statement of Changes in Shareholders' Equity
          -Nine months ended March 31, 2007                                      F-4

     Condensed Consolidated Statements of Cash Flows - Nine months ended
          March 31, 2007 and 2006                                                F-5

     Notes to Condensed Consolidated Financial Statements                        F-7

Item 2.  Management's Discussion and Analysis                                     1

Item 3. Controls and Procedures                                                   4

Item 3(A)T.  Controls and Procedures                                              4

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings -Not Applicable                                        4

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds              5


Item 3.  Defaults Upon Senior Securities - Not Applicable                         5

Item 4.  Submission of Matters to a Vote of Security Holders - Not Applicable     5

Item 5.  Other Information - Not Applicable                                       5

Item 6.  Exhibits                                                                 6

SIGNATURES                                                                        7
</TABLE>


<PAGE>
<TABLE>
<CAPTION>
                          PART I - FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS
                            VYTA CORP AND SUBSIDIARIES
                       Condensed Consolidated Balance Sheet
                                  March 31, 2007
                                    (Unaudited)

                                Assets
                                ------
<S>                                                                  <C>
Current assets:
  Cash and cash equivalents                                          $    249,688
  Prepaid expenses                                                         89,276
                                                                     -------------
    Total current assets                                                  338,964
                                                                     -------------

Property and equipment:
  Office equipment and furniture                                           67,107
  Less accumulated depreciation                                           (60,323)
                                                                     -------------
                                                                            6,784
                                                                     -------------

Other assets:
  Deposits and other                                                       19,543
  Notes receivable, equity investee (Note 2)                            1,526,899
  Investments in equity investee(Note 3)                                  229,904
                                                                     -------------
                                                                        1,776,346
                                                                     -------------

      Total assets                                                   $  2,122,094
                                                                     =============

                 Liabilities and Shareholders' Equity
                 ------------------------------------

Current liabilities:
  Accounts payable                                                   $     59,464
  Accounts payable, related party                                          22,713
  Accrued liabilities                                                       7,063
  Note payable (Note 4)                                                    50,000
                                                                     -------------
    Total liabilities  (all current)                                      139,240
                                                                     -------------

Commitments and contingencies (Notes 4 and 6)

Shareholders' equity:
  Preferred stock; $0.0001 par value; 5,000,000 shares authorized;
    Series A, 8%; deemed par value $1.00 per share;
    500,000 shares issued and outstanding; liquidation preference
    of $503,100                                                      $    503,100
  Common stock; $0.0001 par value; 200,000,000 shares authorized;
    25,753,512 shares issued and outstanding                                2,575
  Additional paid-in capital                                           29,734,222
  Accumulated other comprehensive income                                  130,719
  Accumulated deficit                                                 (28,387,762)
                                                                     -------------
      Total shareholders' equity                                        1,982,854
                                                                     -------------

        Total liabilities and shareholders' equity                   $  2,122,094
                                                                     =============
</TABLE>

See notes to condensed consolidated financial statements.


                                     F-1
<PAGE>
<TABLE>
<CAPTION>
                                 VYTA CORP AND SUBSIDIARIES
                      Condensed Consolidated Statements of Operations
                                        (Unaudited)

                                             Three Months Ended       Nine Months Ended
                                                 March 31,                March 31,
                                        -------------------------  ------------------------
                                            2007         2006         2007         2006
                                        ------------  -----------  -----------  -----------
<S>                                     <C>           <C>          <C>          <C>
Revenues                                $         -            -            -            -
                                        ------------  -----------  -----------  -----------

General and administrative expense,
  including stock-based compensation
  expense of $625,250 for the three
  and nine months ended March 31, 2007   (  879,058)  (  250,519)  (1,425,825)  (  691,546)
                                        ------------  -----------  -----------  -----------

Loss from operations                       (879,058)  (  250,519)  (1,425,825)    (691,546)
                                        ------------  -----------  -----------  -----------

Other income (expense):
  Other income                                    -            -            -       28,585
  Interest income                                 6       31,895           18       40,245
  Equity losses of equity investees
   (Note 3)                              (  381,574)  (   40,242)  (  921,715)  (  429,896)
  Loss on revaluation of derivative
   warrant liability                              -   (   70,137)           -   (   74,295)
  Interest expense                                -            -            -   (  235,131)
  Interest expense, related party                 -            -            -   (      219)
                                        ------------  -----------  -----------  -----------
                                           (381,568)  (   78,484)  (  921,697)  (  670,711)
                                        ------------  -----------  -----------  -----------

Net loss                                 (1,260,626)  (  329,003)  (2,347,522)  (1,362,257)
                                        ------------  -----------  -----------  -----------

Deemed dividends on preferred stock          (3,100)           -       (3,100)           -

Beneficial conversion feature                     -   (1,500,000)           -   (1,500,000)
                                        ------------  -----------  -----------  -----------

Net loss applicable to common
  shareholders                          $(1,263,726)  (1,829,003)  (2,350,622)  (2,862,257)
                                        ============  ===========  ===========  ===========

Net loss per share, basic and diluted
  (Note 1)                              $     (0.05)   (    0.11)  (     0.10)       (0.29)
                                        ============  ===========  ===========  ===========

Weighted average number of common
  shares outstanding (Note 1)            22,781,734   16,972,602   22,688,913    9,818,450
                                        ============  ===========  ===========  ===========
</TABLE>

     See notes to condensed consolidated financial statements.


                                     F-2
<PAGE>
<TABLE>
<CAPTION>
                                 VYTA CORP AND SUBSIDIARIES
                  Condensed Consolidated Statements of Comprehensive Loss
                                        (Unaudited)

                                         Three Months Ended           Nine Months Ended
                                             March 31,                    March 31,
                                     --------------------------  --------------------------
                                         2007          2006          2007          2006
                                     ------------  ------------  ------------  ------------
<S>                                  <C>           <C>           <C>           <C>
Net loss                             $(1,260,626)  (   329,003)  ( 2,347,522)  ( 1,362,257)

Change in unrealized gain (loss) on
  securities                                 189   (       371)          360          (385)
                                     ------------  ------------  ------------  ------------


Comprehensive loss                   $(1,260,437)  (   329,374)  ( 2,347,162)   (1,362,642)
                                     ============  ============  ============  ============
</TABLE>

See notes to condensed consolidated financial statements.


                                     F-3
<PAGE>
<TABLE>
<CAPTION>
                                                VYTA CORP AND SUBSIDIARIES
                            Condensed Consolidated Statement of Changes in Shareholders' Equity
                                              Nine Months Ended March 31, 2007
                                                        (Unaudited)

                                                                             Accumulated
                                                                Additional      other                           Total
                       Preferred stock        Common stock       paid in    comprehensive    Accumualted    shareholders'
                      Shares    Amount      Shares    Amount     capital        income         deficit         equity
                      -------  ---------  ----------  -------  -----------  --------------  -------------  ---------------
<S>                   <C>      <C>        <C>         <C>      <C>          <C>             <C>            <C>
Balances, July 1,
  2006                      -  $       -  22,643,512  $ 2,264  $28,390,883  $      130,359  $(26,037,140)  $    2,486,366

Series A preferred
  stock issued in
  exchange for
  advance payable
  related   party
  and cash            500,000    500,000           -        -            -               -             -          500,000

Warrant issued
  for cash                  -          -           -        -      251,900               -             -          251,900

Common stock
  issued for cash           -          -   3,110,000      311      466,189               -             -          466,500

Options issued
  for  compensation         -          -           -        -      625,250               -             -          625,250

Net loss                    -          -           -        -            -               -   ( 2,347,522)      (2,347,522)

Deemed dividends on
  Series A
  preferred stock           -      3,100           -        -            -               -        (3,100)               -

Change in
  unrealized
  gain on securities        -          -           -        -            -             360             -              360
                      -------  ---------  ----------  -------  -----------  --------------  -------------  ---------------
Balances,
  March 31, 2007      500,000  $ 503,100  25,753,512  $ 2,575  $29,734,222  $      130,719  $(28,387,762)  $    1,982,854
                      =======  =========  ==========  =======  ===========  ==============  =============  ===============
</TABLE>

See notes to condensed consolidated financial statements.


                                     F-4
<PAGE>
<TABLE>
<CAPTION>
                                VYTA CORP AND SUBSIDIARIES
                     Condensed Consolidated Statements of Cash Flows
                                       (Unaudited)

                                                                   Nine Months Ended
                                                                       March 31,
                                                              ---------------------------
                                                                  2007           2006
                                                              -------------  ------------
<S>                                                           <C>            <C>
Cash flows from operating activities:
  Net loss                                                    $ (2,347,522)   (1,362,257)
                                                              -------------  ------------
  Adjustments to reconcile net loss to net cash used
    in operating activities:
    Amortization expense                                           349,068        67,561
    Depreciation expense                                             4,041         4,281
    Equity losses of equity investees                              921,715       429,896
    Options issued for compensation                                625,250             -
    Amortization of discounts on notes payable                           -       213,760
    Loss on revaluation of derivative warrant
      liability (Note 5)                                                 -        74,295
  Changes in operating assets and liabilities:
    Increase in interest and other receivable                            -   (    11,607)
    Decrease (increase) in prepaid expenses                         14,435   (    15,623)
    Increase (decrease) in accounts payable and accrued
      liabilities                                                    4,917       (52,473)
                                                              -------------  ------------
 Total adjustments                                               1,919,426       710,090
                                                              -------------  ------------

    Net cash used in operating activities                      (   428,096)     (652,167)
                                                              -------------  ------------

Cash flows from investing activities:
  Increase in notes receivable                                 (   682,975)  (   875,000)
  Payment on note receivable                                             -       275,442
  Investment in joint venture                                            -      (500,000)
                                                              -------------  ------------
    Net cash used in investing activities                      (   682,975)  ( 1,099,558)
                                                              -------------  ------------

Cash flows from financing activities:
  Exercise of warrants, and common stock and warrants issued
    for cash                                                       466,500     2,167,372
  Proceeds applied to preferred stock and
    warrant purchase (Note 5)                                      651,900       494,922
  Payment of notes payable                                               -   (   960,663)
  Proceeds from note payable                                        50,000             -
  Proceeds from issuance of notes payable and common stock               -       150,000
                                                              -------------  ------------
    Net cash provided by financing activities                    1,168,400     1,851,631
                                                              -------------  ------------

Net increase in cash and cash equivalents                           57,329        99,906

Cash and cash equivalents, beginning                               192,359        25,835
                                                              -------------  ------------

Cash and cash equivalents, ending                             $    249,688       125,741
                                                              =============  ============


(Continued)
</TABLE>


                                     F-5
<PAGE>
<TABLE>
<CAPTION>
                              VYTA CORP AND SUBSIDIARIES
                    Condensed Consolidated Statements of Cash Flows
                                      (Unaudited)
                                       Continued

                                                                   Nine Months Ended
                                                                       March 31,
                                                               -----------------------
                                                                  2007         2006
                                                               -----------  ----------
<S>                                                            <C>          <C>
Supplemental disclosure of cash flow information:
  Cash paid for interest                                       $         -     23,569
                                                               ===========  ==========
Supplemental disclosure of non-cash investing and financing
  activities:
   Advances, related party converted to preferred stock
     (Note 5)                                                  $   100,000          -
                                                               ===========  ==========
   Issuance of Series A Preferred Stock in exchange for note
     receivable                                                $         -  1,100,000
                                                               ===========  ==========
   Beneficial conversion feature                               $         -  1,500,000
                                                               ===========  ==========
   Reclassification of derivative warrant liability to
     equity                                                    $         -    253,521
                                                               ===========  ==========
   Issuance of common stock in connection with notes payable   $         -    117,886
                                                               ===========  ==========
   Issuance of common stock in exchange for accrued
     commissions                                               $         -     90,000
                                                               ===========  ==========
   Advances receivable applied to equity investment            $         -    405,000
                                                               ===========  ==========
   Equity investment acquired in exchange for note payable     $         -    595,000
                                                               ===========  ==========
  Liability recorded for offering costs of common stock
    issuance                                                   $         -    800,000
                                                               ===========  ==========
  Forgiveness of offering costs owed in connection with
    common stock issuance                                      $         -   (800,000)
                                                               ===========  ==========
  Forgiveness of accrued payroll owed to
    officer/shareholder                                        $         -      8,750
                                                               ===========  ==========
</TABLE>

See notes to condensed consolidated financial statements.


                                     F-6
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2007 and 2006
                                   (Unaudited)


1.    BASIS  OF  PRESENTATION,  MANAGEMENT'S  PLANS  AND SUMMARY OF  SIGNIFICANT
      ACCOUNTING  POLICIES:

Presentation of Interim Information:

The  accompanying  condensed  consolidated  financial  statements  include  the
accounts  of  Vyta  Corp,  a  Nevada corporation (the Company), its wholly-owned
subsidiaries,  NanoPierce Connection Systems, Inc., a Nevada corporation (NCOS),
and  ExypnoTech,  LLC  (ET  LLC).  All  significant  intercompany  accounts  and
transactions  have  been  eliminated  in  consolidation.  NCOS and ET LLC had no
revenues  or  operations in 2007 and 2006. The Company has two investments which
are  accounted  for  using  the equity method of accounting. These equity method
investments  consist  of  ExypnoTech, GmbH (EPT) and BioAgra, LLC (BioAgra)(Note
3).  The  Company's  equity  investees,  EPT  and  BioAgra,  operate  in  two
segments,  the  RFID  industry  and  the  animal  feed  industry,  respectively.

In  the  opinion  of  the  management of the Company, the accompanying unaudited
condensed  consolidated  financial  statements include all material adjustments,
including  all normal and recurring adjustments, considered necessary to present
fairly  the  financial  position  and  operating  results of the Company for the
periods  presented.  The  financial  statements  and  notes  are  presented  as
permitted by Form 10-QSB, and do not contain certain information included in the
Company's  Annual Report on Form 10-KSB for the fiscal year ended June 30, 2006.
It  is  management's opinion that when the interim financial statements are read
in  conjunction  with  the  June  30,  2006  Annual  Report  on Form 10-KSB, the
disclosures  are  adequate  to  make  the  information presented not misleading.
Interim results are not necessarily indicative of results for a full year or any
future  period.

Management's  Plans:

In the Company's Annual Report on Form 10-KSB for the fiscal year ended June 30,
2006,  the  Report of the Independent Registered Public Accounting Firm includes
an  explanatory  paragraph  that describes substantial doubt about the Company's
ability  to  continue  as  a  going  concern.  The  Company's  interim financial
statements  for  the  nine  months  ended March 31, 2007 have been prepared on a
going  concern  basis,  which  contemplates  the  realization  of assets and the
settlement of liabilities and commitments in the normal course of business.  The
Company  reported  a  net loss of $2,347,522 for the nine months ended March 31,
2007,  and  an  accumulated  deficit  of  $28,387,762 as of March 31, 2007.  The
Company  has  not  recognized  any  revenues  from  its  business  operations.


                                     F-7
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2007 and 2006
                                   (Unaudited)


The  Company's  ability  to  continue as a going concern may be dependent on the
success  of  management's plans discussed below. The financial statements do not
contain  any  adjustments  relating  to the recoverability and classification of
assets  or the amounts and classification of liabilities that might be necessary
should  the  Company  be  unable to continue as a going concern. During the 2007
fiscal year, the Company intends to continue its efforts to assist BioAgra (Note
3)  with  the continuing development of sales, nationally and internationally in
other  animal  feed  markets,  such  as  the  equine  and  the swine markets. In
addition,  in  January 2007 the Company signed a Technology Agreement to license
its  NCOS(TM)  technology.

The  Company  has  raised  funds  through  the  issuance of a preferred stock, a
warrant  and  shares  of  its  restricted  common  stock. The Company intends to
continue  to  raise  funds  to support operations through the sale of its equity
securities.

Currently,  the  Company  does  not  have  a  revolving  loan agreement with any
financial institution, nor can the Company provide any assurance it will be able
to  enter  into  any  such  agreement  in  the future, or be able to raise funds
through  a  further  issuance  of  debt  or  equity  in  the  Company.

Deferred Consulting Costs:

In  June  2006,  the  Company  entered  into  a twelve-month consulting services
agreement  with  two  third  parties,  in  which  the  parties agreed to provide
lobbying  and public relation services. Compensation consisted of 200,000 shares
of  the  Company's  common  stock  with a market value of approximately $182,000
(based  on a closing market price of $0.91 per share at the date the transaction
was  entered  into)  and  a  warrant to purchase 500,000 shares of the Company's
common  stock,  with an exercise price of $0.91 per share and a term of 3 years.
The  warrant  was  valued at $283,000 using the Black-Scholes pricing model. The
deferred  cost  is  being  amortized on a straight-line basis as earned over the
twelve-month period from the date of the agreement. During the nine months ended
March  31,  2007,  $349,068  was  expensed.

In  June  2005,  the  Company  entered  into  a twelve-month consulting services
agreement  with  a third party, in which this party agreed to provide public and
investor  relation  services  and general business services for the twelve-month
term  of  the  agreement.  Compensation  consisted  of  1,000,000  shares of the
Company's  restricted  common stock with a market value of approximately $90,000
(based  on  the  closing  market  price  of  $0.09  per share at the date of the
transaction).  The  deferred  cost  was  amortized  on  a straight-line basis as
earned over the twelve-month period from the date of the agreement and therefore
has  been fully amortized.  During the nine months ended March 31, 2006, $67,561
was  expensed.

Loss Per Share:

Basic  Earnings  Per  Share  (EPS)  excludes dilution.  Diluted EPS reflects the
potential  dilution  that  could occur if securities or other contracts to issue
common  stock  were  exercised or converted into common stock or resulted in the
issuance  of  common stock that then shared in the earnings of the entity.  Loss
per  share  of  common stock is computed based on the weighted average number of
common  shares  outstanding  during  the  period.  Stock  options  and


                                     F-8
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2007 and 2006
                                   (Unaudited)


warrants  are  not considered in the calculation, as the impact of the potential
common shares (15,392,134 shares at March 31, 2007 and 6,029,468 shares at March
31,  2006)  would  be  to  decrease loss per share.  Therefore, diluted loss per
share  is  equivalent  to  basic  loss  per  share.

Stock-Based Compensation:

Beginning  July  1, 2006, the Company adopted the provisions of and accounts for
stock-based  compensation  in  accordance with Statement of Financial Accounting
standards  No.  123  -  revised 2004 ("SFAS 123R"), "Share-Based Payment", which
replaced  Statement  of  Financial  Accounting  Standards  No. 123 ("SFAS 123"),
"Accounting  for  Stock-based  Compensation",  and supersedes APB Opinion No. 25
("APB  25"),  Accounting  for  Stock  Issued to Employees". Under the fair value
recognition  provisions  of  this  statement,  stock-based  compensation cost is
measured  at  the  grant  date  based  on  the  fair  value  of the award and is
recognized  as  expenses  on  a  straight-line  basis over the requisite service
period,  which  is  the  vesting  period.  The  Company  elected  the
modified-prospective  method,  under  which  prior  periods  are not revised for
comparative  purposes. The valuation provisions of SFAS 123R apply to new grants
and  to  grants  that  were  outstanding  as  of  the  effective  date  and  are
subsequently  modified.  All  options granted prior to the adoption of SFAS 123R
and  outstanding  during  the  periods  presented  were  fully-vested.

The  Company  has  two  stock  option  plans which permit the grant of shares to
attract,  retain  and  motivate  employees,  directors  and consultants of up to
2,863,000  shares  of  common  stock.  Options  are  generally  granted  with an
exercise  price  equal  to the Company's market price of its common stock on the
date  of  the  grant  and  with  vesting  rates,  as  determined by the Board of
Directors.  All  options  outstanding  at  July  1,  2006 and March 31, 2007 are
fully-vested  and  exercisable.

During the nine months ended March 31, 2007, the Company granted 2,050,000 stock
options  to  an officer, directors and an employee at an exercise price of $0.32
per share. The fair value of stock options at the date of grant was $625,250 and
was  recorded  as  compensation  expense.  The  Company  used  the  following
assumptions  to  determine the fair value of stock option grants during the nine
months  ended  March  31,  2007:

<TABLE>
<CAPTION>
                                                  2007
                                               ----------
                      <S>                      <C>
                      Expected life              5 years
                      Volatility                     172%
                      Risk-free interest rate       4.94%
                      Dividend yield                   0
</TABLE>

The  Company  did  not  grant any options during the nine months ended March 31,
2006.

The  expected term of stock options represents the period of time that the stock
options  granted  are  expected  to  be outstanding based on historical exercise
trends.  The  expected volatility is based on the historical price volatility of
the  Company's  common  stock.  The  risk-free interest rate represents the U.S.
Treasury  bill  rate  for  the  expected  life  of  the  related  stock options.


                                     F-9
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2007 and 2006
                                   (Unaudited)


The  dividend  yield represents  our anticipated cash dividend over the expected
life  of  the  stock  options.

A  summary  of stock option activity for the nine months ended March 31, 2007 is
presented  below:

<TABLE>
<CAPTION>
                                                          Weighed
                                             Weighted     Average
                               Shares Under   Average    Remaining   Aggregate
                                  Option     Exercise   Contractual  Intrinsic
                                               Price       Life        Value
                               ------------------------------------------------
<S>                            <C>           <C>        <C>          <C>
Outstanding at June 1, 2006         398,126  $   22.00   4.60 years  $        -
  Granted                         2,050,000       0.32   9.96 years           -
  Exercised                               -          -            -           -
  Expired                                 -          -            -           -
                               ------------  ---------  -----------  ----------
Outstanding at March 31, 2007     2,448,126  $    4.00   3.87 years  $        -
                               ============  =========  ===========  ==========

Exercisable at March 31, 2007     2,448,126  $    4.00   3.87 years  $        -
                               ============  =========  ===========  ==========
</TABLE>

At March 31, 2007, all outstanding and exercisable options were fully vested.

Recently  Issued  Accounting  Standards:

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements". This
statement  defines  fair value, establishes a framework for measuring fair value
in  generally accepted accounting principles, and expands disclosures about fair
value measurements. This statement applies under other accounting pronouncements
that  require  or  permit fair value measurements. SFAS No. 157 is effective for
the  Company  for  its  fiscal  year  beginning  on July 1, 2008. The Company is
currently  assessing  the  impact  the adoption of SFAS No. 157 will have on its
consolidated  financial  statements.

In  September  2006,  the  SEC issued Staff Accounting Bulletin (SAB) No. 108 in
order  to  eliminate  the diversity of practice surrounding how public companies
quantify  financial  statement  misstatements.  In  SAB  108,  the  SEC  staff
established  an  approach  that  requires  quantification of financial statement
misstatements based on the effects of the misstatements on each of the Company's
financial  statements  and  the related financial statement disclosures. SAB No.
108  is  effective  for the Company for its current fiscal year. The adoption of
SAB  No.  108  did  not  have  an impact on the Company's consolidated financial
statements.

2.   NOTES RECEIVABLE - EQUITY INVESTEE:

During  the  year  ended  June  30,  2006,  the  Company  loaned  $1,726,827  to
BioAgra(Note 3) in exchange for a secured, 7.5% promissory note with payments to
be  made  monthly starting October 31, 2006, through October 31, 2007. The funds
were  loaned to facilitate BioAgra's completion of its first production line and
to  support  operations.  The  promissory  note is collateralized by all BioAgra
assets.  Additionally,  the  promissory  note is to be paid in full prior to any
distributions  being  made  to the members of the joint venture. During the nine
months  ended March 31, 2007, the note was reduced by $882,903, which represents
the  excess  of  the  BioAgra  losses  recognized  by  the  Company  over


                                      F-10
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2007 and 2006
                                   (Unaudited)


the  adjusted  basis  of the Company's equity investment in BioAgra remaining at
March  31,  2007  (Note  3).

During  the nine months ended March 31, 2007, the Company advanced an additional
$682,975  to  BioAgra.  On  March  30,  2007, the Company executed a second 7.5%
promissory note for $682,975 with BioAgra with the same terms as the note above,
but the note did not provide for scheduled payments.  The Company has classified
these  notes  receivable  as  long-term  assets  on the balance sheet and is not
accruing  interest  on  these notes receivable, as they are currently in default
and  non-performing.

3.   INVESTMENTS IN AFFILIATES:

Investment in EPT:

The  carrying amount of the Company's investment in EPT is $229,904 at March 31,
2007,  and  is  adjusted to recognize the Company's proportionate share of EPT's
income  (loss)  each  period.

Unaudited  financial  information  of EPT as of March 31, 2007, and for the nine
and  three-month  periods  ended  March  31,  2007  and  2006  are  as  follows:

<TABLE>
<CAPTION>
                                                                                March 31,2007
                                                                               --------------
          <S>                                                                  <C>
          Assets:
            Current assets(1)                                                  $    1,295,384
            Equipment                                                                  26,376
                                                                               --------------

          Total assets                                                         $    1,321,760
                                                                               ==============

          Liabilities and members' equity:
            Current liabilities(2)                                             $      978,436
            Members' equity                                                           343,324
                                                                               --------------

          Total liabilities and members' equity                                $    1,321,760
                                                                               ==============
</TABLE>

(1)  Current  assets  include  receivables of $641,722 due from the 51% owner of
     EPT.
(2)  Current  liabilities  include  a payable of $29,473 due to the 51% owner of
     EPT.


                                      F-11
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2007 and 2006
                                   (Unaudited)


<TABLE>
<CAPTION>
                Three           Three
                Months         Months         Nine Months    Nine Months
                Ended           Ended            Ended          Ended
              March 31,       March 31,         March 31,      March 31,
                 2007           2006              2007           2007
             ------------  ---------------  ---------------  ------------
<S>          <C>           <C>              <C>              <C>
Revenues(1)    1,023,658          821,429        2,863,398     1,866,625
Expenses(2)   (1,048,604)        (638,675)      (2,723,595)   (1,780,275)
             ------------  ---------------  ---------------  ------------
Net income
  (loss)     $   (24,946)         182,754          139,803        86,350
             ============  ===============  ===============  ============
</TABLE>

     (1)  Revenues  for  the  nine  months ended March 31, 2007 and 2006 include
          $2,863,398  and  $1,550,832, respectively ($1,023,658 and $505,710 for
          the three months ended March 31, 2007 and 2006, respectively) of sales
          to  the  51%  owner  of  EPT  for  each  period  presented.
     (2)  Expenses  for  the  nine  months ended March 31, 2007 and 2006 include
          $148,456  and $83,525, respectively ($67,779 and $37,854 for the three
          months ended March 31, 2007 and 2006, respectively) of charges paid to
          the  51%  owner  of  EPT  for  each  period  presented.

Investment in BioAgra:

The  terms  of the BioAgra joint venture provide for the Company to share in 50%
of  joint  venture  net  income,  if  any, or net losses. Net losses incurred by
BioAgra  have exceeded the underlying equity attributed to BioAgra's other joint
venture  investor.  As  a  result,  the excess of the losses attributable to the
other  joint  venture investor have been charged to the Company. Since September
30,  2006  and  through  March  31,  2007  the  carrying  value of the Company's
investment  in  BioAgra  was $0. BioAgra losses for the three months ended March
31, 2007 ($369,351) were applied to reduce the value of the note receivable from
BioAgra.


                                      F-12
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2007 and 2006
                                   (Unaudited)


Unaudited  financial  information  of  BioAgra  as of March 31, 2007 and for the
three  months  ended  March  31,  2007,  and  the  period  from  August 15, 2005
(inception) through March 31, 2006 and the three months ended March 31, 2006, is
as  follows:

<TABLE>
<CAPTION>
                                                       March 31, 2007
                                                      ----------------
          <S>                                         <C>
          Assets:
            Current assets                            $       189,654
            Land, building and equipment, net(2)            1,871,966
            Other assets, net                                 994,754
                                                      ----------------

          Total assets                                $     3,056,374
                                                      ================

          Liabilities and members' equity:
            Current liabilities(1)                    $     2,967,422
            Obligation under capital lease(2)                 971,854
                                                      ----------------

          Total liabilities                                 3,939,276

          Members' deficiency                              (  882,902)
                                                      ----------------

          Total liabilities and members' deficiency   $     3,056,374
                                                      ================
</TABLE>

     (1)  Includes  $2,406,002  owed  to  the  Company.

     (2)  BioAgra  leases  land  and  a  building  under  a  ten-year  lease
          expiring  in  February 2015, which requires a monthly lease payment of
          $12,000.

<TABLE>
<CAPTION>

          Three Months   Three Months    Nine Months     August 15,
              Ended          Ended          Ended       2005 through
            March 31,      March 31,      March 31,       March 31,
              2007           2006            2007           2006
          -------------  -------------  --------------  -------------
<S>       <C>            <C>            <C>             <C>
Revenues         1,675              -   $      33,317              -
Expenses     ( 371,026)   (   259,584)   (  1,023,536)      (944,416)
          -------------  -------------  --------------  -------------
Net loss     ( 369,351)   (   259,584)  $    (990,219)     ( 944,416)
          =============  =============  ==============  =============
</TABLE>

4.   NOTES PAYABLE,  RELATED  PARTY:

In  March  2007,  a  shareholder of the Company loaned $50,000 to the Company in
exchange  for  an  unsecured,  8%  note payable due in March 2008.

5.   SHAREHOLDERS'  EQUITY

Preferred Stock

In  February  2007,  the  Company sold 500,000 shares of Series A Nonconvertible
Preferred Stock for $500,000 cash to Arizcan Properties, Ltd. (Arizcan). Arizcan
had  advanced the funds to the Company, prior to the issuance of the shares. The
shares provide that when voting as a single class, the shares have the votes and
the  voting power that at all times is greater by 1% than the combined votes and
voting  power  of  all  other  classes  of  securities  entitled  to vote on any


                                      F-13
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2007 and 2006
                                   (Unaudited)


matter.  As  a result of the issuance, Arizcan acquired approximately 51% of the
voting  power  of  the Company. The Company has a right, solely at the Company's
discretion,  to  redeem  the  shares  in  ten years at 130% of deemed par value.

The  holder  of  the  Series  A  Nonconvertible Preferred Stock is entitled to a
dividend  equal to 8% per annum of the Deemed Par Value ($1.00 per share). Also,
the  holder  is entitled to a liquidation preference of the Deemed Par Value for
each outstanding share and any accrued but unpaid dividends upon the liquidation
of  the  Company.

Common  Stock

In  March  2007,  the  Company  issued 3,110,000 shares of its restricted common
stock  for $466,500 cash. The shares were sold for $0.15 per share (based upon a
50%  discount from the closing market price, $0.30 per share, on the date of the
transaction).

In  April 2007, the Company issued 300,000 shares of its restricted common stock
for  $45,000  cash.  The  shares were sold for $0.15 per share (based upon a 53%
discount  from  the  closing  market  price, $0.32 per share, on the date of the
transaction).

Warrant

In February 2007, the Company sold to Arizcan, a warrant exercisable immediately
for  up to 6,000,000 shares of restricted common stock for $251,900. The warrant
has an exercise price of $0.50 per share and provides for cashless exercise. The
warrant  has  a  term  of  5  years.

6.   COMMITMENTS AND CONTINGENCIES

LITIGATION:

Depository  Trust  Suit:

In  May  2004,  the Company filed suit against the Depository Trust and Clearing
Corporation  ("DTCC"),  the  Depository  Trust Company ("DTC"), and the National
Securities  Clearing  Corporation ("NSCC") in the Second Judicial District Court
of the County of Washoe, State of Nevada. The suit alleges multiple claims under
the  Nevada  Revised  Statutes  90.570, 90.580, 90.660 and 598A.060 and on other
legal  bases.  The complaint alleges, among other things, that the DTCC, DTC and
NSCC  acted in concert to operate the "Stock Borrow Program," originally created
to  address  short  term delivery failures by sellers of securities in the stock
market. According to the complaint, the DTCC, NSCC and DTC conspired to maintain
significant  open  fail deliver positions of millions of shares of the Company's
common  stock  for extended periods of time by using the Stock Borrow Program to
cover these open and unsettled positions. The Company was seeking damages in the
amount  of  $25,000,000 and treble damages. Responsive pleadings have been filed
by  the  defendants.  In  April  2005, the court granted a motion to dismiss the
lawsuit.  The  Company has filed an appeal to overturn the motion to dismiss the
lawsuit.

Financing  Agreement  Suit:

In  connection  with  a  financing  obtained  in October 2000, the Company filed
various actions in the United States District Court for the District of Colorado
against,  among others, Harvest Court, LLC, Southridge Capital Investments, LLC,
Daniel  Pickett,  Patricia  Singer and Thomson Kernaghan, Ltd. for violations of
federal  and  state  securities laws, conspiracy, aiding and abetting and common
law  fraud  among  other  claims.  As  a  result  of  various


                                      F-14
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2007 and 2006
                                   (Unaudited)


procedural  rulings,  in  January 2002, the United States District Court for the
District  of  Colorado  transferred the case to the United States District Court
for  the  Southern  District  of  New  York,  New  York City, New York.  In this
litigation,  Harvest  Court,  LLC  filed  counterclaims  against the Company and
certain  officers  and  former  board  members  of  the Company, and a number of
unrelated  third  parties.  The  counterclaims  allege  violations  of  federal
securities  laws and other laws.  Harvest Court, LLC is seeking various forms of
relief  including  compensatory and punitive damages.  Responsive pleadings have
been  filed  and  the  litigation  is  currently  in  the  discovery  stage.

In  May  2001,  Harvest Court, LLC filed suit against the Company in the Supreme
Court  of  the  State of New York, County of New York. The suit alleges that the
Company  breached  an  October 20, 2000 Stock Purchase Agreement, by not issuing
7,418,895  free  trading shares of the Company's common stock in connection with
the  reset provisions of the Purchase Agreement due on the second reset date and
approximately  4,500,225  shares  due  in  connection with the third reset date.
Harvest  Court,  LLC  is  seeking  the delivery of such shares or damages in the
alternative.  In August 2001, the Supreme Court of the State of New York, County
of  New York issued a preliminary injunction ordering the Company to reserve and
not  transfer  the  shares allegedly due to Harvest Court, LLC (832,029 shares).
The  Company  has  filed  counterclaims  seeking various forms of relief against
Harvest  Court,  LLC.

The Company intends to vigorously prosecute this litigation and does not believe
the  outcome  of  this  litigation  will  have  a material adverse effect on the
financial  condition,  results  of  operations  or  liquidity  of  the  Company.
However, it is too early at this time to determine the ultimate outcome of these
matters.


                                      F-15
<PAGE>
ITEM 2. MANAGEMENT'S  DISCUSSION  AND  ANALYSIS

     Certain  statements  contained in this Form 10-QSB contain "forward-looking
statements"  within  the meaning of the Private Securities Litigation Reform Act
of  1995  and involve risks and uncertainties that could cause actual results to
differ  materially  from  the  results,  financial  or  otherwise,  or  other
expectations  described in such forward-looking statements.  Any forward-looking
statement  or statements speak only as of the date on which such statements were
made,  and  the  Company  undertakes no obligation to update any forward-looking
statement  to  reflect  events  or  circumstances  after  the date on which such
statements  are  made  or  reflect  the  occurrence  of  unanticipated  events.
Therefore, forward-looking statements should not be relied upon as prediction of
actual  future  results.

     The independent registered public accounting firm's report on the Company's
consolidated financial statements as of June 30, 2006, and for each of the years
in  the  two-year  period  then  ended,  includes  a "going concern" explanatory
paragraph,  that  describes  substantial  doubt  about  the Company's ability to
continue  as  a  going  concern.  Management's  plans  in  regard to the factors
prompting  the  explanatory  paragraph are discussed below and also in Note 1 to
the  unaudited  quarterly  financial  statements.

RESULTS  OF  OPERATIONS

     The Company had no revenues during the nine months ended March 31, 2007 and
2006.

     Total  general  and  administrative  expenses  during the nine months ended
March  31,  2007  were $1,425,825 compared to $691,546 for the nine months ended
March  31, 2006 ($879,058 and $250,519 for the three months ended March 31, 2007
and  2006,  respectively).  The  nine-month  increase  of $734,279, is primarily
attributable  as  set  forth  on  the  table  below.

<TABLE>
<CAPTION>
                     General and                    $Increase or
                 Administrative Expense              (Decrease)
          ----------------------------------  -----------------------
          <S>                                 <C>
          Stock-based compensation            $              625,250
          Consulting expenses                                296,350
          Accounting expenses                                 12,214
          Commission fees                                    (70,010)
          Legal expense                                      (23,254)
          Rent expense                                       (24,974)
          Public relations                                   (23,857)
</TABLE>

     In  the  three  months  ended March 31, 2007, the Company granted 2,050,000
stock  options  to an officer, directors and an employee at an exercise price of
$0.19 per share. The fair value of stock options at the date of grant during the
three  months  ended March 31, 2007 was $625,250, which has been expensed by the
Company.

     The  Company  recognized  $40,245 in interest income during the nine months
ended  March  31,  2006. ($31,895 during the three months ended March 31, 2006).
During  the  nine months ended March 31, 2006, the Company recognized $28,585 in
other  income,  which  represented  a  gain  on  the  extinguishment  of certain
liabilities.


                                        1
<PAGE>
     The  Company  recognized  interest  expense of $235,350 for the nine months
ended  March  31,  2006  ($0  for the three months ended March 31, 2006). Of the
$235,350  in  interest  expense,  $219  represented  related party interest. The
remaining  $235,131  was  incurred in connection with the issuance of promissory
notes,  which  were discounted for the fair value of warrants included with debt
at  the time of issuance. The resulting discounts ($213,760) were amortized over
the  term of the promissory notes. The promissory notes were paid in full during
the  three  months ended September 30, 2005, and at that time the discounts were
fully  amortized.

During  the  nine months ended March 31, 2007, the Company recognized a net loss
of  $2,347,522 compared to a net loss of $1,362,257 during the nine months ended
March  31,  2006  ($1,260,626  and $329,003 for the three months ended March 31,
2007  and  2006, respectively). The increase of $985,265, during the nine months
ended  March  31, 2007, is primarily attributable to the increase of $734,279 in
general  and  administrative  expenses  and  the net increase of $491,819 in the
losses  of  the  Company's  equity  investments.

LIQUIDITY  AND  FINANCIAL  CONDITION

     During  the  nine months ended March 31, 2007, the Company used $428,096 in
operating  activities. Net cash provided by financing activities was $1,168,400,
of  which  $400,000  was from the sale of preferred stock, $718,400 was from the
sale  of  common  stock  and a warrant, and $50,000 was from a note payable. Net
cash used in investing activities was $682,975, which was advanced to BioAgra to
be  used  to  support  its operations. The Company had $249,688 of cash and cash
equivalents at March 31, 2007, which is being used to support operations. During
the  nine  months  ended  March 31, 2006, the Company used $652,167 in operating
activities.  During  the  nine months ended March 31, 2006, net cash provided by
financing  activities  was $1,851,631; of which $2,167,372 was from the exercise
of  warrants,  $494,922  was from the sale of preferred stock, $150,000 was from
the  issuance  of  notes  payable  and common stock and $960,663 was used to pay
notes  payable.

     In  August  2005, the Company purchased a 50% equity interest in BioAgra (a
Georgia  limited  liability  company)  for  $905,000  cash  (which  includes the
$405,000  advanced to Xact Resources during the fiscal year ended June 30, 2005)
and  a  note  payable  of  $595,000  which  was  paid in full in September 2005.
BioAgra  is  to manufacture and sell a beta glucan product, YBG-2000 marketed as
AgriStim,  to  be  used  as  a  replacement  for  hormone  growth  steroids  and
antibiotics  in animal feed products.  BioAgra has completed the construction of
its  production  line,  and during the nine months ended March 31, 2007, BioAgra
had  limited sales of its product.  During the nine months ended March 31, 2007,
BioAgra has been working with potential customers on field testing trials of the
AgriStim  product.  In  April  2007, BioAgra signed an agreement with a customer
for  the  purchase  and  resale  of  its  AgriStim  product.

     As  of  March  31,  2007,  if all existing outstanding warrants issued in a
January  2004  private placement were exercised, the Company will be required to
issue an additional 1,342,500 shares of common stock and would receive $192,125,
and  the Company, on a fully diluted basis (including the reservation of 832,029
shares  as  required  by  the  court  in  the  Financing


                                        2
<PAGE>
Agreement  Litigation),  would have 41,145,646 shares of common stock issued and
outstanding.

     However,  no  assurance  can  be  given  that any of these warrants will be
exercised.  If  the  warrants are exercised, the Company has decided that it may
use the additional funds received from the exercise of these warrants to support
the  operations  of  the  Company  and  its  investments.

     During the 2007 fiscal year, the Company intends to continue its efforts to
aid  BioAgra  with  the  continuing  development  of  its  sales, nationally and
internationally  in  other animal feed markets, such as the equine and the swine
markets.   In  addition,  in  January  2007,  the  Company  signed  a  six-month
Technology Agreement to permit a prospective licensee the opportunity to conduct
a  market  survey  relating to its NCOS(TM) technology.   We believe that if the
market  survey  is  favorable the Technology Agreement may mature into a royalty
paying  commercial  license  the  terms  and  conditions  of  which  are  under
negotiation  between  the  Company  and  the  perspective  licensee.

     The  Company intends to raise additional funds to support operations of the
Company  during  the  2007  fiscal  year.  Such  funds  are to be raised through
offerings  of  the  Company's  common  stock.

     To  the  extent  the  Company's  operations  are not sufficient to fund the
Company's  capital  requirements  the  Company  may  enter into a revolving loan
agreement  with  financial  institutions or attempt to raise capital through the
sale  of  additional  capital  stock  or  through  the issuance of debt.  At the
present  time  the  Company  does  not  have a revolving loan agreement with any
financial  institution nor can the Company provide any assurance that it will be
able  to  enter  into any such agreement in the future or be able to raise funds
through  the  further  issuance  of  debt  or  equity  in  the  Company.


RECENTLY  ISSUED  ACCOUNTING  STANDARDS:

     In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements".
This  statement  defines  fair value, establishes a framework for measuring fair
value in generally accepted accounting principles, and expands disclosures about
fair  value  measurements.  This  statement  applies  under  other  accounting
pronouncements  that require or permit fair value measurements.  SFAS No. 157 is
effective  for  the  Company for its fiscal year beginning on July 1, 2008.  The
Company is currently assessing the impact the adoption of SFAS No. 157 will have
on  its  consolidated  financial  statements.

     In  September  2006,  the  SEC issued SAB No. 108 in order to eliminate the
diversity  of  practice  surrounding  how  public  companies  quantify financial
statement misstatements.  In SAB 108, the SEC staff established an approach that
requires  quantification  of  financial  statement  misstatements  based  on the
effects  of  the misstatements on each of the Company's financial statements and
the  related  financial statement disclosures.  SAB No. 108 is effective for the
Company  for  its current fiscal year.  The adoption of SAB No. 108 did not have
an  impact  on  the  Company's  consolidated  financial  statements.


                                        3
<PAGE>
ITEM 3. CONTROLS  AND  PROCEDURES

As  of  the  end  of the period covered by this Quarterly Report on Form 10-QSB,
the  Company  carried  out  an  evaluation,  under  the supervision and with the
participation  of  the  Company's  President and Chief Financial Officer, of the
effectiveness  of  the design and operation of the Company's disclosure controls
and  procedures  (as such term is defined in Rules 13a-14(c) and 15d-14(c) under
the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based upon
such  evaluation,  such  officers  have  concluded that the Company's disclosure
controls  and  procedures  are  effective as of the end of the period covered by
this  quarterly  report  on  Form 10-QSB in alerting them, on a timely basis, to
material  information  relating  to  the  Company required to be included in the
Company's  periodic  SEC  filings  and to ensure that information required to be
disclosed  in the Company's periodic SEC filings is accumulated and communicated
to  the  Company's  management,  including  its  President  and  Chief Financial
Officer,  to  allow  timely  decisions  regarding  required  disclosure.

There  was  no  change  to  the  Company's  internal  controls  over  financial
reporting  during  the  fiscal  quarter ended March 31, 2007 that has materially
affected,  or  is reasonably likely to materially affect, the Company's internal
controls  over  financial  reporting.


ITEM 3(A)T.  CONTROLS  AND  PROCEDURES

There  have been no changes in the small business issuer's internal control over
financial  reporting  identified  in  connection with the evaluation required by
paragraph  (d)  of  Rule  240.15d-15  that  occurred  during  the small business
issuer's  last  fiscal  quarter  that  has materially affected, or is reasonable
likely  to  materially affect, the small business issuer's internal control over
financial  reporting.


                           PART II - OTHER INFORMATION

ITEM 1. LEGAL  PROCEEDINGS  -  NO  CHANGE.


                                        4
<PAGE>
ITEM 2. UNREGISTERED  SALES  OF  EQUITY  SECURITIES  AND  USE  OF  PROCEEDS

     The  Company  made  the following unregistered sales of its securities from
January  1,  2007  through  March  31,  2007.

<TABLE>
<CAPTION>
DATE OF SALE  TITLE OF SECURITIES  NO. OF SHARES  CONSIDERATION   CLASS OF PURCHASER
------------  -------------------  -------------  --------------  -------------------
<S>           <C>                  <C>            <C>             <C>
-------------------------------------------------------------------------------------
  2/27/07     Preferred Stock            500,000  $      500,000  Business Associate
-------------------------------------------------------------------------------------
  3/2/07      Warrant                  6,000,000  $      251,900  Business Associate
-------------------------------------------------------------------------------------
  3/27/07     Common Stock             3,110,000  $      466,500  Business Associates
</TABLE>

Exemption From Registration Claimed

     All of the sales by the Company of its unregistered securities were made by
the  Company  in  reliance  upon  Section 4(2) of the Securities Act of 1933, as
amended  (the  "1933  Act").  The  entity  listed  above  that  purchased  the
unregistered  securities  was  an existing shareholder, known to the Company and
its  management, through pre-existing business relationships, as a long standing
business associate.  The entity was provided access to all material information,
which it requested, and all information necessary to verify such information and
was  afforded  access  to  management  of  the  Company  in  connection with the
purchases.  The  purchaser  of  the  unregistered  securities  acquired  such
securities for investment and not with a view toward distribution, acknowledging
such  intent  to  the  Company. All certificates or agreements representing such
securities  that  were issued contained restrictive legends, prohibiting further
transfer of the certificates or agreements representing such securities, without
such  securities  either  being  first  registered  or  otherwise  exempt  from
registration  in  any  further  resale  or  disposition.


ITEM  3.  DEFAULTS  UPON  SENIOR  SECURITIES  -  NONE.

ITEM  4.  SUBMISSION  OF  MATTERS  TO  A  VOTE  OF  SECURITY  HOLDERS  -  NONE.

ITEM  5.  OTHER  INFORMATION  -  NONE.


                                        5
<PAGE>
ITEM 6. EXHIBITS

     EXHIBITS.  The  following  is  a  complete  list  of exhibits filed as part
     of  this  Form  10-QSB.  Exhibit  numbers  correspond to the numbers in the
     Exhibit  Table  of  Item  601  of  Regulation  S-B.

          Exhibit 31.1  Certification  of  Chief  Executive  Officer pursuant to
                        Section  302  of  the  Sarbanes-Oxley  Act

          Exhibit 32.1  Certification  of  Principal  Executive  Officer
                        pursuant  to  Section  906  of  the Sarbanes-Oxley Act


                                        6
<PAGE>
                                   SIGNATURES

     In accordance with the requirements of the Securities Exchange Act of 1934,
the  registrant  has  duly  caused this report to be signed on its behalf by the
undersigned,  thereunto  duly  authorized.

                                                   VYTA CORP
                                                  (REGISTRANT)

Date:  May  20,  2007                   /s/  Paul  H.  Metzinger
                                        ----------------------------------------
                                               Paul  H.  Metzinger,
                                               President  &  CEO
                                               (Principle  Executive  Officer)


                                       7